Benign Prostatic Hyperplasia Medical Services in China

Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland commonly affecting men over 50. As the prostate grows, it compresses the urethra, leading to lower urinary tract symptoms—including urinary frequency, nocturia, weak stream, hesitancy, incomplete bladder emptying, and, in advanced cases, acute urinary retention or bladder stone formation. While BPH is not associated with increased prostate cancer risk, untreated progression may cause irreversible bladder dysfunction, upper urinary tract dilation, or renal impairment. Diagnosis relies on clinical assessment (IPSS questionnaire), digital rectal examination, uroflowmetry, post-void residual volume measurement, and transrectal ultrasound; PSA testing helps exclude concurrent malignancy. Management ranges from watchful waiting and alpha-blockers/5-alpha-reductase inhibitors to minimally invasive procedures (e.g., transurethral resection of the prostate—TURP, holmium laser enucleation—HoLEP, or bipolar vaporization) and, rarely, open prostatectomy.

China offers distinct advantages for BPH treatment: its urology centers—especially tier-1 hospitals in Beijing, Shanghai, and Guangzhou—employ internationally trained specialists with extensive experience in high-volume, complex cases. Advanced technologies such as thulium and holmium lasers, image-guided ablation systems, and robotic-assisted platforms are widely available and routinely used. Clinical outcomes align with global benchmarks: HoLEP demonstrates >95% symptom improvement at 5-year follow-up, with low retreatment rates. Crucially, costs for surgical intervention in China are typically 40–60% lower than in the US or Western Europe—without compromising safety or efficacy. As a dedicated medical tourism agency, we facilitate seamless care for international patients: verifying hospital accreditation, coordinating consultations and surgery scheduling, providing transparent all-inclusive pricing (covering diagnostics, procedure, accommodation, and interpreter services), and offering end-to-end support—from visa assistance to postoperative follow-up coordination.

Medical Travel to China Guide: Benign Prostatic Hyperplasia (BPH)

Most nationalities require a Chinese visa for medical treatment; we assist with the Medical Visa (Q2 or S2) application, providing invitation letters from partner hospitals and guiding document preparation. Upon arrival, patients undergo streamlined entry with health declaration support. Regarding payment, China does not accept most international health insurance directly—however, our agency offers transparent, all-inclusive pricing packages covering consultation, diagnostics, surgery (e.g., HoLEP or TURP), and post-op care, with upfront cost breakdowns in USD/GBP/EUR. We accept bank transfers, credit cards, and secure escrow payments. Accommodation options include hospital-adjacent serviced apartments or 4-star hotels with Wi-Fi, daily cleaning, and kitchen access; companions are welcome and may stay at discounted rates. Our dedicated care coordinators arrange airport transfers, interpreter services, and local logistics. Crucially, follow-up care is fully supported: we schedule virtual consultations with treating urologists at 1, 3, and 6 months post-discharge, share digital medical records, and coordinate with your home physician for continuity. All services are managed end-to-end by our bilingual patient advocates—ensuring clarity, comfort, and clinical confidence throughout your BPH journey in China.